Cargando…
Mutational Signature and Transcriptomic Classification Analyses as the Decisive Diagnostic Tools for a Cancer of Unknown Primary
PURPOSE: Cancer of unknown primary is a group of metastatic tumors in which the standard diagnostic workup fails to identify the site of origin of the tumor. The potential impact of precision oncology on this group of patients is large, because actionable driver mutations and a correct diagnosis cou...
Autores principales: | Bagge, Roger Olofsson, Demir, Akif, Karlsson, Joakim, Alaei-Mahabadi, Babak, Einarsdottir, Berglind O., Jespersen, Henrik, Lindberg, Mattias F., Muth, Andreas, Nilsson, Lisa M., Persson, Marta, Svensson, Johanna B., Söderberg, Elin M.V., de Krijger, Ronald R., Nilsson, Ola, Larsson, Erik, Stenman, Göran, Nilsson, Jonas A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446430/ https://www.ncbi.nlm.nih.gov/pubmed/32913988 http://dx.doi.org/10.1200/PO.18.00002 |
Ejemplares similares
-
A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma
por: Einarsdottir, Berglind O., et al.
Publicado: (2018) -
Correction: A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma
por: Einarsdottir, Berglind O., et al.
Publicado: (2020) -
Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions
por: Einarsdottir, Berglind O., et al.
Publicado: (2014) -
BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Veppil Muralidharan, Somsundar, et al.
Publicado: (2017) -
BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Muralidharan, Somsundar Veppil, et al.
Publicado: (2017)